促血小板生成素调控慢性肝病患者血小板的作用及其临床应用  

Recent advance of pathogenesis of TPO in thrombocytes and its clinical use in patients with chronic liver disease

作　　者：皮赛男 李亮[2] 杨默 陈友鹏 PI Sainan;LI Liang;YANG Mo;CHEN Youpeng(Department of Infectious Diseases,the Seventh Affiliated Hospital,Sun Yat-sen University,Shenzhen 518107,China;Scientific Research Center,the Seventh Affiliated Hospital,Sun Yat-sen University,Shenzhen 518107,China)

机构地区：[1]中山大学附属第七医院感染性疾病科,广东深圳518107 [2]中山大学附属第七医院科研中心,广东深圳518107

出　　处：《新医学》2024年第9期745-750,共6页Journal of New Medicine

基　　金：广东省基础与应用基础研究基金项目(2021A1515111034);深圳市科技计划项目(JCYJ20190809180211430,JCYJ-20190809180213349)。

摘　　要：慢性肝病患者常有血小板减少,其发生机制复杂且尚未被阐明。随着近年来对慢性肝病合并血小板减少的研究深入,研究者们意识到慢性肝病患者的血小板减少不仅与脾功能亢进有关,而且促血小板生成素在其中也起到一定程度的调控作用,文章提出“肝源性促血小板生成素中心的肠-肝调控网络机制”的可能性,就促血小板生成素调控血小板的作用、慢性肝病患者血小板的生物学功能、促血小板生成素在慢性肝病和肝硬化的诊断,以及促血小板生成素与促血小板生成素受体激动剂在慢性肝病血小板减少的治疗应用等方面的研究进展进行综述,为基础及临床相关研究提供新的思路。Patients with chronic liver disease frequently exhibit thrombocytopenia,the etiology of which is intricate and not yet fully understood.As research into the association between chronic liver disease and thrombocytopenia has progressed in recent years,investigators have recognized that the thrombocytopenia in these patients is not solely attributed to splenic hyperfunction but is also modulated to a certain extent by thrombopoietin(TPO).The article posits the possibility of a“liver-derived thrombopoietincentered gut-liver regulatory network mechanism”,providing a comprehensive review of the role of TPO in platelet regulation,the biological functions of platelets in patients with chronic liver disease,the diagnostic implications of TPO in chronic liver disease and cirrhosis,and the therapeutic applications of TPO and TPO receptor agonists in the treatment of thrombocytopenia in chronic liver disease.This review offers novel insights for both basic science and clinical research.

关 键 词：促血小板生成素 慢性肝病 肝硬化 血小板 促血小板生成素受体激动剂 

分 类 号：R575[医药卫生—消化系统]